Neuropharmacological actions of cigarette smoke: Brain monoamine oxidase B (MAO B) inhibition

Journal of Addictive Diseases

Volumn 17, Issue 1, 1998, Pages 23-34

  Fowler, J S ^a   Volkow, N D ^a,b   Wang, G J ^a   Pappas, N ^a   Logan, J ^a   Macgregor, R ^a   Alexoff, D ^a   Wolf, A P ^a   Warner, D ^a   Cilento, R ^a   Zezulkova, I ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BRAIN ENZYME; CIGARETTE SMOKE;

ADULT; AGED; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; MALE; NEUROPHARMACOLOGY; POSITRON EMISSION TOMOGRAPHY;

EID: 0031971072     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v17n01_03     Document Type: Article

References (39)

1. Henningfield JE, Schuh LM, Jarvik ME. Pathophysiology of tobacco de-pendence. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology, the Fourth Generation of Progress. Chapter 147. New York: Raven Press Ltd, 1995:1715-1729.
2. Jarvik ME, Schneider NG. In: Johnson JH, Ruiz R, Millman RB, Langood JG, eds. Substance-Abuse-A Comprehensive Textbook (2nd edition), Chapter 25 Baltimore: Williams and Wilkens, 1992:334-356.
3. Schelling TC. Addictive drugs: the cigarette experience. Science 1992; 255:430-433.
4. Baron JA. Cigarette smoking and Parkinson’s disease. Neurology 1986; 36:1490-1496.
5. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson’s disease: false association or etiological clue. Neurology 1995; 45:1041-1051.
6. Hughes JR, Hatsukama DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993-997.
7. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, Johnson J. Smoking, smoking cessation, and major depression. JAMA 1990; 264: 1546-1549.
8. Henningfield JE, Clayton R, Pollen W. Involvement of tobacco in alcoholism and illictit drug use. Br J Addiction 1990; 85:279-292.
9. Singer T. Monoamine oxidases: old friends hold many surprises. FASEB J 1995;9:605-610.
10. Oreland L, Fowler CJ, Schalling D. Low platelet monoamine oxidase activity in cigarette smokers. Life Sci 1981; 29:2511-2518.
11. Norman TR, Chamberlain KG, French MA. Platelet monoamine oxidase: low activity in cigarette smokers. Psychiatry Res 1987; 20:199-205.
12. Yong VW, Perry TL. Monoamine oxidase B, smoking, and Parkinson’s disease. J. Neurological Sci 1986; 72:265-272.
13. Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay J-M, Puech AJ. Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry 1995; 38:756-761.
14. Yu PH, Boulton AA. Irreversible inhibition of MAO by some components of cigarette smoke. Life Sci 1987; 41:675.
15. Pavlin R, Sket D. Effect of cigarette smoke on brain monoamine oxidase activity. Farm vestn 1993; 44:185-192.
16. Carr LA, Basham JK. Effects of tobacco smoke constituents on MPTP-indiced toxicity and monoamine oxidase activity in the mouse brain. Life Sci 1991; 48:1173-1177.
17. Boulton AA, Yu PH, Tipton KF. Biogenic amine adducts, monoamine oxidase inhibitors, and smoking. Lancet 1988; 1:114-115.
18. Fowler JS, Wang G-J, Logan J, Xie S, Volkow ND, MacGregor RR, Schlyer DJ, Pappas N, Alexoff DL, Patlak C, Wolf AP. Selective reduction of radiotracer trapping by deuterium substitution: comparison of [nC]L-deprenyl and [11C]L-deprenyl-D2 for MAO B mapping. JNuclMed. 1996; 36:1255-1262.
19. Fowler JS, Wang G-J, Volkow ND, Pappas N, Logan J, MacGregor RR, Alexoff D, Wolf AP, Warner D, Cilento R, Zezulkova I. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379:733-736.
20. Fowler JS, Wolf AP, MacGregor RR, Dewey SL, Logan J, Schlyer DJ, Langström B. Mechanistic PET studies: demonstration of a deuterium isotope effect in the MAO catalyzed binding of [nC]L-deprenyl in living baboon brain. J Neurochem. 1988;51:1524-1534.
21. Alexoff DL, Shea C, Wolf AP, Fowler JS, King P, Gatley SJ, Schlyer DJ. Plasma input function determination for PET using a commercial laboratory robot. Nucl. Med. Biol. 1995; 22:893-904.
22. Wang G-J, Volkow ND, Wolf AP, Brodie JD, Hitzemann R. Intersubject variability of brain glucose metabolic measurements in young normal males. J Nucl Med. 1994; 35:1457-1466.
23. Matsui T, Hirano A. An atlas of the human brain for computerized tomo-graphy. Stuttgart: Gustav Fischer, 1978.
24. Koeppe RA, Holthoff A, Frey KA, Kilbourn MR, Kuhl DE. Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood FlowMetab. 1991; 11:735-744.
25. Logan J, Dewey SL, Wolf AP, Fowler JS, Brodie JD, Angrist B, Volkow ND, Gatley SJ. Effects of endogenous dopamine on measures of [18F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 1991; 9:195-207.
26. Fowler JS, Volkow ND, Logan J, Schlyer DJ, MacGregor RR, Wang G-J, Wolf AP, Pappas N, Alexoff D, Shea C, Dorflinger E, Yoo K, Morawsky L, Fazzini E. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson’s disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327 Neurology 1993; 43:1984-1992.
27. Patlak C, Fenstermacher JD, Blasberg RG. Graphical evaluation of bloodto-brain transfer constants from multiple timeactivity data. J. Cereb. Blood Flow Metab. 1983; 3:1-7.
28. Blomqvist G. On the construction of functional maps in positron emission tomography. J. Cereb. Blood Flow Metab. 1984; 4:629-632.
29. Walpole RE, Myers RH. Tests of hypotheses. In: Probability and Statistics for Engineers and Scientists., 2nd edition, MacMillan Publishing Co. Inc. 1978: 256-259.
30. Yamashita K, Kobayashi S, Yamaguchi S, Kitani M, Tsunematsu T. Effect of smoking on regional cerebral blood flow in the normal aged volunteers. Gerontology 1988; 34:199-204.
31. Fowler JS, Volkow ND, Logan J, Wang G-J, MacGregor RR, Schlyer D, Wolf AP, Pappas N, Alexoff D, Shea C, Dorflinger E, Krochowy L, Yoo K, Fazzini E, Patlak C. Slow recovery of human brain MAO B after L-deprenyl (selegeline) withdrawal. Synapse 1994; 18: 86-93.
32. Glover V, Sandler M, Owen F, Riley GJ. Dopamine is a monoamine oxidase B substrate in man. Nature 1977; 265:80-81.
33. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Nat Acad USA. 1988; 85:5274-5278.
34. Pontieri FE, Tanda G, Orzi F, Di Chiera G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996; 382: 255-257.
35. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977; 34:33-35.
36. Reiter RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J. 1995; 9:526-533.
37. Tetrud JW, Langston JW. The effect of deprenyl (selegeline) on the natural history of Parkinson’s disease. Science 1989; 245:519-522.
38. Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. New Eng J Med. 1988;319:1318-1330.
39. Berlin I, Said S, Spreux-Varoquaux O, Launay J-M, Olivares R, Millet V, Lecrubier Y, Puech AJ. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. ClinPharmac Ther 1995; 58:444-452.